March 20th 2023
Combination treatment with nivolumab and relatlimab appears to be a safe treatment option for patients with advanced melanoma who have progressed on prior anti–PD-L1 therapy.
February 28th 2023
February 28th 2023
February 23rd 2023
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?May 15th 2018
In this review, we highlight prospective data on checkpoint inhibition alone and in combination, discuss data regarding the efficacy and toxicity of combination therapy, and identify clinical scenarios that may favor treatment with combination therapy.
Using Genomic Sequencing to Improve Management in MelanomaMarch 15th 2018
Here we summarize the available genomic and genetic tests for melanoma, and the level of evidence supporting each of these. We also discuss the current impact of genomic sequencing on the management of melanoma, as well as roles it may play in the near future.
Some Melanoma Respond to Immunotherapy Beyond ProgressionJanuary 22nd 2018
Some patients with unresectable or metastatic melanoma who receive immunotherapy and who continue therapy after progression have decreased tumor burden, and survival is improved when the therapy is continued as well, according to a new pooled analysis.
Dabrafenib/Trametinib Granted Priority Review for Stage III BRAF-Mutated MelanomaJanuary 4th 2018
The FDA has granted priority review to the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations after complete disease resection.
Mucosal Melanoma: New Insights and Therapeutic Options for a Unique and Aggressive DiseaseNovember 15th 2017
Here, we review the features of mucosal melanoma that distinguish it from melanomas arising at other sites, and we highlight recent biological discoveries and emerging treatment options for this aggressive disease.